Skip to Content

Join the 'Taxol' group to help and get support from people like you.

Taxol News

Less Chemo for Obese Ovarian Cancer Patients Linked to Worse Survival Rates

Posted 6 Jul 2015 by

MONDAY, July 6, 2015 – Ovarian cancer patients who are overweight or obese are often given lower doses of chemotherapy per pound of body weight, but this may reduce the odds of survival, a new study suggests. "There is a lot of uncertainty in what proper chemotherapy dosing levels should be for overweight and obese patients, based on concerns that using the full dose based on weight or body size could be too toxic," study author Dr. Elisa Bandera, an epidemiologist at Rutgers Cancer Institute of New Jersey, explained in an institute news release. "Our study is the first to evaluate the impact of dose reduction in survival after an ovarian cancer diagnosis in normal weight, overweight and obese women," Bandera said. "We found that for each body mass index category, ovarian cancer patients with dose reduction experienced a poorer survival rate." The study involved 806 women with ovarian ... Read more

Related support groups: Obesity, Ovarian Cancer, Taxol, Carboplatin, Paclitaxel, Onxol, Carboplatin Novaplus, Paraplatin

Drug-Coated Balloon Catheter Approved

Posted 13 Oct 2014 by

MONDAY, Oct. 13, 2014 – The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration. The Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter has a balloon coated with the drug paclitaxel, which may help prevent re-narrowing of the affected artery after the clearing procedure, the FDA said. The device is approved to clear vessels clogged by Peripheral Artery Disease (PAD), which causes hardening and narrowing of the arteries and limits distribution of oxygen-rich blood. Symptoms may include leg pain, skin ulcers or gangrene. The device was evaluated in clinical studies involving more than 500 people. In one study after six months, about 72 percent of those treated with the Lutonix device did not require additional treatment for PAD, compared to nearly ... Read more

Related support groups: Peripheral Arterial Disease, Taxol, Paclitaxel, Onxol

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Provera, Amoxicillin, Depo-Provera, Doxycycline, Metronidazole, Cephalexin, Clindamycin, Penicillin, Methotrexate, Bactrim, Azithromycin, Cipro, Ciprofloxacin, Accutane, Augmentin, Levaquin, Lupron, Flagyl, Keflex, Zithromax

Fine-Tuning Breast Cancer Treatments: What Works Better?

Posted 3 Jun 2013 by

MONDAY, June 3 – Two common schedules used for the chemotherapy paclitaxel (Taxol) are equally effective at controlling breast cancer, but fewer side effects are found with the weekly regimen rather than every two weeks, according to a new study. The estimated five-year progression-free survival rates were the same for both groups, said Dr. G. Thomas Budd, who led the study. While 82 percent of the group treated weekly had progression-free survival five years later, 81 percent of the every two weeks group did. However, "for the weekly group, overall the side effects seem fewer, particularly the aches and pains," said Budd, a professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western University, in Ohio. He is due to present his findings Monday at the annual meeting of the American Society of Clinical Oncology, in Chicago. In another study, also to be ... Read more

Related support groups: Breast Cancer, Taxol, Paclitaxel, Onxol

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Femara, Fluorouracil, Lupron Depot, Gleevec, Rituxan, Isotretinoin, Claravis, Votrient, Avastin, Anastrozole

FDA Medwatch Alert: Hospira Injectable Drug Products: Recall - Visible Particulates from Defective Glass Vials

Posted 18 Jul 2012 by

Including certain lots of the following products: carboplatin cytarabine paclitaxel methotrexate [Posted 07/16/2012] ISSUE: Hospira and FDA notified healthcare professional of a nationwide recall of certain injectable drug products, due to visible particles embedded in the glass located at the neck of the vial. There may be potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution. In the event in which particulate matter could be injected into a patient, there may be the potential for patient injury where medical intervention may be required. Signs and symptoms might include bleeding, bruising, inflammation, itching, rash, chest pain and respiratory symptoms. See the Press Release for a listing of affected product lot numbers and expiration dates. BACKGROUND: These products were distributed nationwide to ... Read more

Related support groups: Cancer, Methotrexate, Taxol, Carboplatin, Paclitaxel, Cytarabine, Cytosar, Trexall, Cytosar-U, Methotrexate LPF Sodium, Tarabine PFS, Folex PFS, Onxol, Rheumatrex Dose Pack, Carboplatin Novaplus, Paraplatin

'Uncertainty' Remains Over Supply of Key Cancer Drugs

Posted 4 Jun 2012 by

MONDAY, June 4 – John Mahan, a 58-year-old Nashville firefighter battling a gastrointestinal cancer, couldn't believe what he was hearing last July. His doctor had just told him that his clinic had run out of injectable fluorouracil (5-FU), the generic chemotherapy Mahan needed to keep his tumor at bay. "My initial reaction was, 'you've got to be kidding, right?'" he said. Unfortunately, the news was all too real. Mahan was switched to another drug, capecitabine. Taken in pill form, it had the same anti-cancer effectiveness as 5-FU but with more onerous side effects. "It made me feel bad, weak," Mahan said, "just run down, feeling tired all of the time, loss of appetite." At a Monday news briefing at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Mahan spoke on behalf of the thousands of cancer patients who have been hit hard by the recent nationwide ... Read more

Related support groups: Cancer, Methotrexate, Fluorouracil, Colorectal Cancer, Lymphoma, Xeloda, Taxol, Paclitaxel, Hodgkin's Lymphoma, Capecitabine, Head and Neck Cancer, Adrucil, Methotrexate LPF Sodium, Trexall, Folex PFS, Onxol, Rheumatrex Dose Pack

New 'Personalized' Drugs Show Promise Against Melanoma, Lung Cancer

Posted 4 Jun 2012 by

MONDAY, June 4 – There's more encouraging news from the brave new world of "personalized" cancer care, with three drugs showing promise against some of the most common cancers. Two studies to be presented Monday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago focus on drugs that treated advanced melanoma, while a third study looks at a gene-targeted chemotherapy for a subset of lung cancers. All of the drugs seemed effective in these phase 3 trials. Already, targeted medications such as these "are of use in the metastasis [cancer] setting," said ASCO spokeswoman Dr. Sylvia Adams, who moderated a press briefing Sunday on the new trials. "In advanced lung cancer, advanced melanoma, [targeted therapies] are the standard of care," said Adams, an assistant professor in the department of medicine at NYU's Langone Medical Center in New York City. In the past, ... Read more

Related support groups: Cancer, Melanoma, Skin Cancer, Taxol, Paclitaxel, DTIC-Dome, Dacarbazine, Onxol

Older Drug for Advanced Breast Cancer Beat Newer, Pricier Meds

Posted 4 Jun 2012 by

MONDAY, June 4 – Even in the field of cancer treatment, sometimes newer isn't necessarily better. That may be the case for patients with advanced breast cancer, who appeared to fare better in a new study when they took an older drug, Taxol (paclitaxel), instead of two newer and more expensive rivals. Both of those newer medications, Abraxane and Ixempra, failed to outperform Taxol in terms of either survival without progression of disease or the level of the most noxious side effects, the study of almost 800 breast cancer patients found. "These data suggest that similar patients may be appropriately treated with weekly paclitaxel [Taxol]," said study author Dr. Hope Rugo, director of breast oncology and clinical trials at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. She spoke at a news briefing Sunday at the American Society of ... Read more

Related support groups: Breast Cancer, Taxol, Paclitaxel, Abraxane, Ixempra, Ixabepilone, Onxol, Paclitaxel Protein-Bound

Antidepressant Cymbalta Might Ease Chemo-Linked Pain

Posted 4 Jun 2012 by

MONDAY, June 4 – Cancer patients on certain chemotherapies often experience a painful tingling in their extremities called peripheral neuropathy, and a new study suggests the antidepressant Cymbalta may be the first treatment to work against the condition. In the small study, 59 percent of patients who'd experienced peripheral neuropathy said that they gained relief after taking Cymbalta (duloxetine), compared to 39 percent who took a "dummy" pill. Taking Cymbalta daily "decreases chronic chemotherapy-induced neuropathy and pain severity in the majority of patients who take it and it improves function and quality of life," said study author Ellen Lavoie Smith, an assistant professor at the University of Michigan's School of Nursing. She said the drug is also "very well tolerated" by most patients. Smith spoke at a news briefing Sunday at the annual meeting of the American Society of ... Read more

Related support groups: Cymbalta, Cancer, Peripheral Neuropathy, Duloxetine, Taxol, Paclitaxel, Onxol

Many Primary Care Docs Don't Know Long-Term Effects of Chemo: Survey

Posted 16 May 2012 by

WEDNESDAY, May 16 – Many primary care doctors don't know the long-term side effects of the chemotherapy treatments that cancer survivors under their care may have been given, a new survey found. On the other hand, most oncologists – though not all – are familiar with the side effects of four common treatments used to treat breast and colon cancer, according to the results of the survey being presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. "While oncologists commonly identify the main late effects of four common cancer drugs, primary care providers did not," study author Dr. Larissa Nekhlyudov said during a Wednesday news conference. "This is not surprising in that primary care providers have different training and exposure to chemotherapy drugs," she noted. "However, these findings emphasize that in the transition of patients ... Read more

Related support groups: Cancer, Zyprexa, Reglan, Olanzapine, Metoclopramide, Nausea/Vomiting - Chemotherapy Induced, Taxol, Zyprexa Zydis, Cytoxan, Cyclophosphamide, Oxaliplatin, Paclitaxel, Adriamycin, Doxorubicin, Eloxatin, Maxolon, Zyprexa Intramuscular, Onxol, Adriamycin PFS, Neosar

Cancer Patients Should Ask Doctors to Use Simple Terms

Posted 28 Sep 2011 by

WEDNESDAY, Sept. 28 – Cancer patients are often faced with many difficult-to-understand treatment choices that can have serious side effects and even mean the difference between life and death. That's why it's crucial that patients insist doctors use plain language in explaining the options, advised Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a researcher at the U-M Comprehensive Cancer Center. "People are making life and death decisions that may affect their survival and they need to know what they're getting themselves into. Cancer treatments and tests can be serious. Patients need to know what kind of side effects they might experience as a result of the treatment they undergo," Fagerlin said in a university news release. She and her colleagues outlined a number of tips to help patients get the information they need ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Femara, Fluorouracil, Lupron Depot, Gleevec, Lung Cancer, Rituxan, Renal Cell Carcinoma, Colorectal Cancer

Elderly Lung Cancer Patients Can Gain From Two-Drug Chemo: Study

Posted 9 Aug 2011 by

MONDAY, Aug. 8 – Countering conventional wisdom, researchers in France say that elderly lung cancer patients can gain significant benefit from an aggressive, double-barreled chemotherapy that's often used in younger patients. The finding raises questions about standard public health recommendations, such as those issued the American Society of Clinical Oncology in 2004, which advised physicians not to expose elderly patients with non-small cell lung cancer (NSCLC) to the undesirable side effects of combination chemotherapy. Instead, older patients have typically been offered less harsh – but also less effective – chemotherapies containing a single agent. That's because, until now, it's been assumed that the benefits to elderly patients of dual-chemo ("doublet") regimens simply weren't worth their onerous side effects and risks. But, "our study demonstrates clearly that [the doublet] ... Read more

Related support groups: Lung Cancer, Taxol, Carboplatin, Gemzar, Paclitaxel, Gemcitabine, Navelbine, Vinorelbine, Onxol, Carboplatin Novaplus, Paraplatin

New Chemo Regimen May Benefit Ovarian Cancer Patients

Posted 2 Feb 2010 by

SUNDAY, Sept. 20 – Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings. This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous ... Read more

Related support groups: Ovarian Cancer, Taxol, Paclitaxel, Onxol

Taxol Boosts Odds of Chronic Pain

Posted 1 Dec 2009 by

MONDAY, Nov. 30 – The chemotherapy drug paclitaxel (Taxol) increases the risk of chronic neuropathic pain in breast cancer survivors, a new study shows. It included 240 women who took part in clinical trials of Taxol between 1994 and 2001. Those who experienced chemotherapy-induced peripheral neuropathy during their treatment with Taxol were three times more likely to eventually be diagnosed with chronic neuropathic pain. The study is published in the November issue of the Journal of Pain. The findings indicate that patients treated with Taxol should be regularly monitored for neuropathic pain after their chemotherapy ends, said the researchers from the University of Texas M.D. Anderson Cancer Center. In certain cases, patients and doctors should review the risks and benefits for continuing treatment with Taxol if a patient is likely to experience worsening neuropathy, the study ... Read more

Related support groups: Taxol

Ask a Question

Further Information

Related Condition Support Groups

Breast Cancer, Metastatic, Ovarian Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Breast Cancer - Adjuvant, Kaposi's Sarcoma, Wilms' Tumor

Taxol Patient Information at